Using current techniques, Alzheimer’s disease, the most frequent cause of dementia, can only be detected once the typical plaques have formed in the brain. At this point, therapy seems no longer possible. However, the first changes caused by Alzheimer’s take place on the protein level up to 20 years sooner. A two-tier method developed at Ruhr-Universität Bochum (RUB) can help detect the disease at a much earlier stage. The researchers from Bochum published their report in the March 2019 edition of the journal “Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring”.
“This has paved the way for early-stage therapy approaches, where the as yet inefficient drugs on which we had pinned our hopes may prove effective,” says Professor Klaus Gerwert from the Department of Biophysics at RUB.
Protein folds incorrectly
In Alzheimer’s patients, the amyloid beta protein folds incorrectly due to pathological changes long before the first symptoms occur. A team of researchers headed by Klaus Gerwert successfully diagnosed this misfolding using a simple blood test; as a result, the disease can be detected approximately eight years before the first clinical symptoms occur. The test wasn’t suitable for clinical applications however: it did detect 71 per cent of Alzheimer’s cases in symptomless stages, but at the same time provided false positive diagnoses for nine per cent of the study participants. In order to increase the number of correctly identified Alzheimer’s cases and to reduce the number of false positive diagnoses, the researchers poured a lot of time and effort into optimising the test.
As a result, they have now introduced the two-tier diagnostic method. To this end, they use the original blood test to identify high-risk individuals. Subsequently, they add a dementia-specific biomarker, namely tau protein, to run further tests with those test participants whose Alzheimer’s diagnosis was positive in the first step. If both biomarkers show a positive result, there is a high likelihood of Alzheimer’s disease. “Through the combination of both analyses, 87 of 100 Alzheimer’s patients were correctly identified in our study,” summarises Klaus Gerwert. “And we reduced the number of false positive diagnoses in healthy subjects to 3 of 100. The second analysis is carried out in cerebrospinal fluid that is extracted from the spinal cord.
“Now, new clinical studies with test participants in very early stages of the disease can be launched,” points out Gerwert. He is hoping that the existing therapeutic antibodies will still have an effect. “Recently, two major promising studies have failed, especially Crenezumab and Aducanumab – not least because it had probably already been too late by the time therapy was taken up. The new test opens up a new therapy window.”
“Once amyloid plaques have formed, it seems that the disease can no longer be treated,” says Dr. Andreas Nabers, head of the research group and co-developer of the Alzheimer’s sensor. “If our attempts to arrest the progression of Alzheimer’s fail, it will put a lot of strain on our society.”
Sensor test is simple and robust
The blood test has been upgraded to a fully automated process at the RUB Department of Biophysics. “The sensor is easy to use, robust when it comes to fluctuation in concentration of biomarkers, and standardised,” explains Andreas Nabers. “We are now conducting in-depth research to detect the second biomarker, namely tau protein, in the blood, in order to supply a solely blood-based test in future,” concludes Klaus Gerwert.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- A 50-Year-Old Drug Might Find a New Life Treating Alzheimer'son October 12, 2021 at 1:41 pm
National Institute on Aging, NIHAlzheimer’s has always been a poorly understood disease, and that’s raised huge challenges in finding viable treatments. Scientists are even exploring unorthodox ...
- Can an already approved drug treat Alzheimer’s disease?on October 12, 2021 at 1:39 pm
A study led by scientists at Gladstone Institutes and UC San Francisco identified an FDA-approved drug called bumetanide that reverses signs of Alzheimer’s disease in mice and may prevent the disease ...
- New research links personality traits and hallmarks of Alzheimer's diseaseon October 12, 2021 at 1:32 pm
New research from the Florida State University College of Medicine found that changes in the brain associated with Alzheimer's disease are often visible early on in individuals with personality traits ...
- Column: Maria Shriver takes her Alzheimer’s campaign to unusual venue in San Diegoon October 12, 2021 at 12:00 pm
That’s why Maria Shriver staged her Women’s Alzheimer’s Movement fundraising event at the Jamul Casino here on Oct. 1. The veteran news personality and former first lady of California joined with two ...
- Alzheimer’s Association Northwest Ohio Chapter to host Black Community Forum on Nov. 3on October 12, 2021 at 11:00 am
MANSFIELD ꟷ The NECIC Neighborhood Community Outreach Center will be the location of an Alzheimer’s Association Community Forum designed to hear the needs and barriers confronting Blacks seeking Alzhe ...
- HealthWatch: Study Finds Water Pill Lowered Prevalence Of Alzheimer's Diseaseon October 12, 2021 at 9:30 am
The latest in health and fitness headlines ...
- Dementia Spotlight Foundation Presents 9th Annual Alzheimer’s Music Fest, Feb. 4 At Buckhead Theatreon October 12, 2021 at 6:22 am
Nonprofit hosts live fundraising concert featuring legendary bands Cracker, Drivin N’ Cryin, Arrested Development and more! Dementia Spotlight Foundation (DSF) encourages the local community and its ...
- Status Update: Music Lab moving to bigger digs in Yorba Linda; Alzheimer’s fundraising gala nearson October 11, 2021 at 5:14 pm
The Music Lab is moving from its location on Main Street in downtown Yorba Linda to a new spot at the corner of Yorba Linda and Fairmont boulevards. The move to 19851 Yorba Linda Blvd. should be final ...
- Alzheimer’s and COVID-19 severity: A genetic link?on October 11, 2021 at 9:45 am
In an intriguing new study, scientists identify a genetic link between the development of Alzheimer's disease and severe COVID-19 outcomes.
- Older blood pressure drug may reduce Alzheimer's risk, study findson October 11, 2021 at 8:01 am
A diuretic commonly used to treat high blood pressure may help prevent the onset of Alzheimer's disease in people who have a high genetic risk, a study published Monday by Nature Aging found.
via Bing News